To describe the treatment of 11 patients with radiobiologically guided dose-painting radiotherapy and report on toxicity.
Boost volumes were identified with functional magnetic resonance imaging scans in 11 patients with high-risk prostate cancer.
Patients were treated using a dose-painting approach; the boost dose was limited to 86 Gy in 37 fractions, while keeping the rectal normal tissue complication probability to 5-6%. Rotational intensity-modulated radiotherapy was used with daily image guidance and fiducial markers.
The median dose to the prostate (outside the boost volume) and urethra was 75. 4 Gy/37 fractions (range 75. 1-75. 8 Gy), whereas the median boost dose was 83. 4 Gy (range 79. 0-87. 4 Gy). The tumour control probability (TCP) (Marsden model) increased from 71% for the standard plans to 83. 6% [76. 6-86. 8%] for the dose-painting boost plans. The mean (Lyman-Kutcher-Burman) normal tissue complication probability for rectal bleeding was 5. 2% (range 3. 3-6. 2%) and 5. 2% for faecal incontinence (range 3. 6-7. 8%). All patients tolerated the treatment well, with a low acute toxicity profile. At a median follow-up of 36 months (range 24-50) there was no grade 3 late toxicity. Two patients had grade 2 late urinary toxicity (urethral stricture, urinary frequency and urgency), one patient had grade 1 and one grade 2 late rectal toxicity. The mean prostate-specific antigen at follow-up was 0. 81 ng/ml after stopping hormone therapy; one patient relapsed biochemically at 32 months (2. 70 ng/ml).
The toxicity for this radiobiological guided dose-painting protocol was low, but we have only treated a small cohort with limited follow-up time. The advantages of this treatment approach should be established in a clinical trial.
Clinical oncology (Royal College of Radiologists (Great Britain)). 2015 Oct 15 [Epub ahead of print]
J Uzan, A E Nahum, I Syndikus
Physics Department, Clatterbridge Cancer Centre, Bebington, UK. , Physics Department, Clatterbridge Cancer Centre, Bebington, UK. , Radiotherapy Department, Clatterbridge Cancer Centre, Bebington, UK.